- Others(Includes 1 tests)
- Alpha feto protein (afp)
- Pregnancy(Includes 1 tests)
- Beta hcg
- Cancer Markers(Includes 4 tests)
- Ca-125
- Ca 15.3
- Ca 19.9
- Carcino embryonic antigen (cea)
Thyrocare Tumour Panel Female: Empowering Women’s Health with Early Detection
The Thyrocare Tumour Panel Female is a specialized and comprehensive diagnostic package designed to detect and monitor various tumour markers in women. With six essential tests, this blood panel offers valuable insights into potential tumour-related issues, enabling early detection and timely intervention. In this article, we will delve into the significance of each test in the Thyrocare Tumour Panel Female and explore its role in empowering women’s health.
Introduction to Thyrocare Tumour Panel Female
The Thyrocare Tumour Panel Female is a cutting-edge blood test that requires 10-12 hours of fasting before the sample is collected. Fasting ensures accurate results by minimizing the impact of recent food consumption on the test parameters. This diagnostic panel is powered by Thyrocare, a trusted and reliable name in the healthcare industry, known for its commitment to delivering precise and advanced diagnostic services.
Understanding the Test Parameters
ALPHA FETO PROTEIN (AFP) Alpha-fetoprotein (AFP) is a protein produced by the developing fetus during pregnancy. Elevated AFP levels in non-pregnant women can indicate certain cancers, particularly liver cancer and germ cell tumours. In the Thyrocare Tumour Panel Female, AFP levels are measured to monitor and detect potential tumours related to liver and germ cell origins.
PREGNANCY [1] The Pregnancy test in the Thyrocare Tumour Panel Female is specifically included to confirm or rule out pregnancy, as elevated AFP levels can also be seen during pregnancy. This ensures that any potential tumour-related findings are accurately interpreted in non-pregnant women.
BETA HCG Beta-human chorionic gonadotropin (Beta HCG) is another marker that is typically elevated during pregnancy. In non-pregnant women, elevated Beta HCG levels can be associated with certain types of tumours, including germ cell tumours and certain types of ovarian cancers. The Thyrocare Tumour Panel Female includes Beta HCG testing to aid in the early detection of these tumours.
CANCER MARKERS [4] The Cancer Markers in the Thyrocare Tumour Panel Female include CA-125, CA 15.3, CA 19.9, and Carcinoembryonic Antigen (CEA). These markers are proteins that can be elevated in the presence of certain types of cancers, such as ovarian, breast, pancreatic, and colorectal cancers. Regular monitoring of these cancer markers can help in the early detection and management of cancer, increasing the chances of successful treatment.
CA-125 is a marker frequently associated with ovarian cancer. Elevated CA-125 levels can be indicative of ovarian tumours or other conditions affecting the ovaries. In the Thyrocare Tumour Panel Female, CA-125 testing provides valuable information for the early detection of ovarian cancer and related conditions.
CA 15.3 is a marker primarily associated with breast cancer. Elevated CA 15.3 levels can be seen in women with breast cancer or other breast-related conditions. In the Thyrocare Tumour Panel Female, CA 15.3 testing aids in the early detection and monitoring of breast cancer.
CA 19.9 is a marker commonly linked to pancreatic and gastrointestinal cancers. Elevated CA 19.9 levels can indicate the presence of these tumours. The inclusion of CA 19.9 testing in the Thyrocare Tumour Panel Female is essential for the early detection and management of pancreatic and gastrointestinal cancers.
CARCINOEMBRYONIC ANTIGEN (CEA) is a marker found in elevated levels in various types of cancers, including colorectal, lung, and pancreatic cancers. The Thyrocare Tumour Panel Female includes CEA testing to aid in the early detection and monitoring of these cancers.
Significance of Thyrocare Tumour Panel Female
The Thyrocare Tumour Panel Female is a significant diagnostic package that plays a crucial role in empowering women’s health. By monitoring essential tumour markers, this panel enables early detection and intervention, leading to better treatment outcomes. Regular screening with the Thyrocare Tumour Panel Female is particularly crucial for women with a family history of cancer or other risk factors.
Early detection of tumours allows for timely medical intervention, potentially reducing the progression of cancer and improving the quality of life. This comprehensive blood panel empowers women to take proactive steps towards their health and well-being.
Alternative Names for the Profile
The Thyrocare Tumour Panel Female is also known as the “Women’s Tumour Marker Panel” or the “Female Tumour Marker Profile.” These alternative names highlight the focus on detecting and monitoring tumour markers specific to women’s health.
FAQs about Thyrocare Tumour Panel Female
Can the Thyrocare Tumour Panel Female diagnose cancer?
The Thyrocare Tumour Panel Female includes tests for tumour markers that are associated with certain types of cancers. While elevated levels of these markers may indicate the presence of cancer, further diagnostic procedures and imaging studies are required for a confirmed diagnosis.
How often should I undergo the Thyrocare Tumour Panel Female?
The frequency of taking the Thyrocare Tumour Panel Female depends on individual health factors, risk factors, and your healthcare provider’s recommendation. Regular screening is generally advised for women with a family history of cancer or other risk factors.
Can Thyrocare Tumour Panel Female detect all types of cancers?
The Thyrocare Tumour Panel Female includes specific tumour markers associated with certain types of cancers. However, it may not detect all types of cancers. Regular screening, along with other diagnostic procedures, is essential for comprehensive cancer detection.
Is Thyrocare a reliable diagnostic service provider?
Yes, Thyrocare is a highly reputable and trusted name in the healthcare industry, known for its state-of-the-art laboratories and accurate diagnostic services.
How long does it take to get the test results?
After your blood sample is collected, the test results typically take 24 hours to be processed and made available to you through the Thyrocare portal.
Can I trust the results of Thyrocare Tumour Panel Female?
Thyrocare is known for its commitment to accuracy and reliability. The diagnostic center follows stringent quality control measures, ensuring that the test results are precise and trustworthy.
The Thyrocare Tumour Panel Female is a critical diagnostic package designed to empower women’s health through the early detection and monitoring of tumour markers. By regularly screening for these markers, women can take proactive steps towards their well-being and increase the chances of successful treatment if cancer is detected. Prioritize your health by considering the Thyrocare Tumour Panel Female and taking charge of your journey to a healthier and more resilient life.